Invuity Inc. (NASDAQ:IVTY) – Sell or Short Recommendation – $11.25 Price Target

December 14, 2015 concludes the 180-day lockup period on Invuity Incorporated.

When the lockup period ends for IVTY, its pre-IPO shareholders, directors and executives will have the chance to sell their 8 million+ shares. The potential for a sudden increase in stock available in the open market may cause a significant decrease in Invuity shares and open a short opportunity for experienced investors.

Business Summary: Medical Technology Company that Produces a Variety of Surgical Devices

(Source)

Based in San Francisco, California, Invuity is a medical technology company that produces surgical devices used in certain surgical procedures in the United States. The company utilizes intelligent photonics technology via its platform to offer reusable, single-use surgical devices to enhance crucial intra-cavity illumination and visual complexities.

The company’s product portfolio includes Eikon illuminated retractor systems used in oncoplastic, breast oncology, orthopedic and other surgeries; Breiten illuminated retractor systems used in spinal surgeries; Eika illuminated retractor systems used in thyroid and cervical spinal surgeries; Saber Yankauer, which is a handheld illuminators for breast, cardiothoracic, spinal and orthopedic operations; Saber Frazier, which is a handheld illuminator, which is another handheld illuminator for certain surgeries, among other devices.

The company markets its devices through its direct sales representatives and original equipment manufacturers of such systems. In addition, it sells directly to surgeons and hospitals.

Invuity notes in its SEC filings that it has transitioned from primarily research and development to the manufacturing and selling of its portfolio. Through March 2015, Invuity had a total of eight lines of illuminated surgical devices comprised of more than 40 separate appliances.

Recently Invuity introduced a new product called Hidden Scar, a program developed to address issues confronted by breast surgery patients. The company expects strong growth in this category.

Print Friendly, PDF & Email